老年多发性骨髓瘤患者血清白细胞介素-2的检测及临床意义

Measurement of serum interleukin 2 in elderly patients with multiple myeloma and its clinical implication

目的检测老年多发性骨髓瘤（ＭＭ）患者血清白细胞介素－２（ＩＬ－２）含量，分析其临床意义。方法用固相放射免疫分析（ＲＩＡ）法检测４４例初诊老年ＭＭ患者、２０例健康老年人和４０例健康青中年人血清ＩＬ－２含量，随访患者３年的存活状况。结果ＭＭ患者血清ＩＬ－２为８．１１±２．５４μｇ／Ｌ，显著高于老年健康对照组的２．６８±０．６１μｇ／Ｌ（Ｐ＜０．０１）。血清ＩＬ－２≥５μｇ／Ｌ的患者３年生存率显著提高。血清ＩＬ－２与血清β２微球蛋白（β２－ＭＧ）有关，血清ＩＬ－２≥５μｇ／Ｌ的患者，β２－ＭＧ皆＜６ｍｇ／Ｌ。结论血清ＩＬ－２的检测可作为估计ＭＭ预后的一项指标。

Objective To find the level of serum interleukin 2(IL 2) in elderly patients with multiple myeloma (MM) and its clinical implication. Methods Serum IL 2 level was detected in 44 newly diagnosed MM patients, 20 elderly healthy controls and 40 young healthy controls with radioimmunoassay (RIA) methods.The survival period of the patients was then followed. Results Serum IL 2 level in MM patients was 8 11±2 54μg/L, but that in elderly healthy controls was 2 68±0 61 μg/L . A statistically significant difference was observed between the patients and the elderly healthy controls ( P <0 01).Three year survival rate in patients with serum IL 2≥5μg/L was higher than in those with IL 2<5μg/L. Furthermore, all patients with serum IL 2≥5μg/L had serum β 2 MG level<6mg/L. By using these two parameters, three groups could be identified and the survival duration was different among the three groups. Conclusions These data indicated that serum IL 2 levels could be used as a reliable factor to predict the prognosis of MM.